Marc Ditmarsch
Corporate Officer/Principal presso FRAZIER LIFESCIENCES ACQUISITION CORPORATION
Patrimonio netto: - $ in data 30/04/2024
Profilo
Marc Ditmarsch is currently the Vice President-Research & Development at NewAmsterdam Pharma Holding BV and the Chief Development Officer at NewAmsterdam Pharma Co. NV.
Previously, he worked as a Medical Director at AstraZeneca BV from 2014 to 2016.
He holds a doctorate degree from Vrije Universiteit Amsterdam.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 22/03/2023 | 0 ( -.--% ) | - $ | 30/04/2024 |
Posizioni attive di Marc Ditmarsch
| Società | Posizione | Inizio |
|---|---|---|
| FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Corporate Officer/Principal | 01/08/2022 |
NewAmsterdam Pharma Holding BV
 NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | Corporate Officer/Principal | 01/01/2020 |
Precedenti posizioni note di Marc Ditmarsch
| Società | Posizione | Fine |
|---|---|---|
| AstraZeneca BV | Direttore Tecnico/Scientifico/R&S | 01/01/2016 |
Formazione di Marc Ditmarsch
| Vrije Universiteit Amsterdam | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| FRAZIER LIFESCIENCES ACQUISITION CORPORATION | Health Technology |
| Aziende private | 2 |
|---|---|
NewAmsterdam Pharma Holding BV
NewAmsterdam Pharma Holding BV BiotechnologyHealth Technology Part of NewAmsterdam Pharma Co. NV, NewAmsterdam Pharma Holding BV is a Dutch company that engages in research and development of transformative therapies for cardio metabolic diseases. The company is based in Naarden, the Netherlands. The company was founded in 2019 by John Jacob Pieter Kastelein. Michael H. Davidson has been the CEO of the company since 2020. NewAmsterdam Pharma Holding was acquired by Frazier Lifesciences Acquisition Corp. on November 22, 2022 for $468.74 million. | Health Technology |
| AstraZeneca BV |
- Borsa valori
- Insiders
- Marc Ditmarsch
